These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17187301)

  • 1. EORTC-NCI-AACR - 18th Symposium - Molecular Targets and Cancer Therapeutics.
    Kibble A
    IDrugs; 2007 Jan; 10(1):1-2. PubMed ID: 17187301
    [No Abstract]   [Full Text] [Related]  

  • 2. AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 3.
    Collins T
    IDrugs; 2007 Dec; 10(12):840-3. PubMed ID: 18041675
    [No Abstract]   [Full Text] [Related]  

  • 3. EORTC-NCI-AACR - 18th Symposium - Molecular Targets and Cancer Therapeutics. Updates on cancer drugs.
    Kibble A
    IDrugs; 2007 Jan; 10(1):3-4. PubMed ID: 17187302
    [No Abstract]   [Full Text] [Related]  

  • 4. AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 4.
    Eccles SA
    IDrugs; 2007 Dec; 10(12):844-7. PubMed ID: 18041676
    [No Abstract]   [Full Text] [Related]  

  • 5. AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 2.
    Searle B; Collins T
    IDrugs; 2007 Dec; 10(12):836-9. PubMed ID: 18041674
    [No Abstract]   [Full Text] [Related]  

  • 6. AACR-NCI-EORTC--21st International Symposium. Molecular targets and cancer therapeutics--Part 2.
    Walker K; Padhiar M
    IDrugs; 2010 Jan; 13(1):10-2. PubMed ID: 20024839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EORTC-NCI-AACR - 18th Symposium - Molecular Targets and Cancer Therapeutics. Pediatric drugs, biomarkers and new therapies.
    Kibble A
    IDrugs; 2007 Jan; 10(1):5-7. PubMed ID: 17187303
    [No Abstract]   [Full Text] [Related]  

  • 8. AACR-NCI-EORTC--21st International Symposium. Molecular targets and cancer therapeutics--Part 1.
    Walker K; Padhiar M
    IDrugs; 2010 Jan; 13(1):7-9. PubMed ID: 20024838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
    Carew JS; Giles FJ; Nawrocki ST
    Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AACR-NCI-EORTC International Conference 2009.
    Awada A; Lacombe D
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):319-20. PubMed ID: 20214512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.
    Wang S
    Oncogene; 2008 Oct; 27(48):6207-15. PubMed ID: 18931688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EORTC-NCI-AACR - 18th Symposium - Molecular Targets and Cancer Therapeutics. New approaches in treating cancer.
    Murch L
    IDrugs; 2007 Jan; 10(1):8-10. PubMed ID: 17187304
    [No Abstract]   [Full Text] [Related]  

  • 13. The TRAIL apoptotic pathway in cancer onset, progression and therapy.
    Johnstone RW; Frew AJ; Smyth MJ
    Nat Rev Cancer; 2008 Oct; 8(10):782-98. PubMed ID: 18813321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).
    Ashkenazi A; Holland P; Eckhardt SG
    J Clin Oncol; 2008 Jul; 26(21):3621-30. PubMed ID: 18640940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is TRAIL the holy grail of cancer therapy?
    Newsom-Davis T; Prieske S; Walczak H
    Apoptosis; 2009 Apr; 14(4):607-23. PubMed ID: 19194800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 1.
    Searle B
    IDrugs; 2007 Dec; 10(12):833-5. PubMed ID: 18041673
    [No Abstract]   [Full Text] [Related]  

  • 18. Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer.
    Frese S; Schüller A; Frese-Schaper M; Gugger M; Schmid RA
    Anticancer Res; 2009 Aug; 29(8):2905-11. PubMed ID: 19661294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRAIL as a target in anti-cancer therapy.
    Wu GS
    Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRAIL-receptor antibodies as a potential cancer treatment.
    Buchsbaum DJ; Forero-Torres A; LoBuglio AF
    Future Oncol; 2007 Aug; 3(4):405-9. PubMed ID: 17661715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.